Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.

The LITESPARK-022 study tested belzutifan, an oral small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α) targeting angiogenesis, in combination with standard of care pembrolizumab as ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

Adding belzutifan to pembrolizumab after kidney cancer surgery cuts recurrence risk by 28%, helping high-risk patients stay ...

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab regimens for patients with PD-L1 positive, platinum-resistant ovarian cancers. A ...

Investigators sought to determine whether adjuvant pembrolizumab is associated with the risk of developing subsequent cutaneous malignant neoplasms in patients with high-risk stage II melanoma.